Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Teva Pharmaceutical Industries' Q4 2024 ... future shareholder-friendly activities like dividends or share repurchases. A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates ...

Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating estimates ... call that kicked off at 8 a.m. ET. TEVA Price Action: Teva Pharmaceutical shares were down 8.78% at ...

Barclays dropped their price objective on Teva Pharmaceutical ... Limited will post 2.62 earnings per share for the current year. Teva Pharmaceutical Industries Limited develops, manufactures ...

Teva Pharmaceutical Industries Ltd. (NYSE ... However, the company's share price opened nearly 10% lower on the NYSE due to a disappointing 2025 outlook. Teva has also provided guidance on ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full year 2024 financial results.

Piper Sandler increased their price target on Teva Pharmaceutical Industries from ... The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0 ...

A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...